Radiotherapy plus immunotherapy with or without chemotherapy improves survival in elderly esophageal squamous cell carcinoma: a real-world comorbidity-stratified study
Frontiers in Oncology · 04.05.2026 · 16
DOI: 10.3389/fonc.2026.1748355 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 04.05.2026. Verfasst von Hong Jian Ren und 4 weiteren Autor:innen. Beteiligte Einrichtung: Fenyang Hospital of Shanxi Province, Fenyang, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
This real-world study explores the efficacy and safety of radiotherapy combined with immunotherapy-based regimens in elderly patients (≥70 years) with esophageal squamous cell carcinoma (ESCC), stratified by the Cumulative Illness Rating Scale--Geriatric (CIRS-G). Given the exploratory nature and modest sample size, findings should be interpreted as hypothesis-generating.
Methods
We conducted a single-center retrospective analysis of 87 elderly ESCC patients receiving intensity-modulated radiotherapy, categorized into three groups: radiotherapy alone (RT, n=49), concurrent chemoradiotherapy (CRT, n=18), and radiotherapy combined with immunotherapy ± chemotherapy (RIT ± CT, n=20). The primary endpoint was overall survival (OS). Propensity score matching (PSM) and multivariable Cox regression were performed.
Results
With a median follow-up of 37 months, multivariable Cox regression analysis suggested that the RIT ± CT regimen was associated with a reduced mortality risk versus RT (HR = 0.341, 95% CI: 0.130–0.896, P = 0.029). PSM confirmed this survival advantage (OS: HR = 0.42, P = 0.028). Patients with a medium CIRS-G burden (scores 4–6) demonstrated the most significant OS benefit from this multimodal strategy. Grade ≥3 TRAEs were highest in the RIT ± CT group (55.0%), with no treatment-related deaths.
Conclusion
The integration of immunotherapy-based regimens into radiotherapy shows an association with improved survival in elderly ESCC patients with a manageable safety profile. The CIRS-G score may help identify optimal candidates. These exploratory findings require validation in larger, prospective multicenter studies. The independent contribution of immunotherapy alone cannot be determined from this study.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Fenyang Hospital of Shanxi Province, Fenyang, China.
- School of Stomatology, Tongji University, Shanghai, China.
Zitieren
APA
Ren, H. J., Ren, Q. L., Zhang, Z. J., Lei, J. J., & Xu, N. (2026). Radiotherapy plus immunotherapy with or without chemotherapy improves survival in elderly esophageal squamous cell carcinoma: a real-world comorbidity-stratified study. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1748355
Vancouver
Ren HJ, Ren QL, Zhang ZJ, Lei JJ, Xu N. Radiotherapy plus immunotherapy with or without chemotherapy improves survival in elderly esophageal squamous cell carcinoma: a real-world comorbidity-stratified study. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1748355
BibTeX
@article{Ren2026,
author = {Ren, Hong Jian and Ren, Qi Lin and Zhang, Zhi Juan and Lei, Jun Jie and Xu, Ning},
title = {Radiotherapy plus immunotherapy with or without chemotherapy improves survival in elderly esophageal squamous cell carcinoma: a real-world comorbidity-stratified study},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1748355}
}
EUVIMED